PlainPharmaWatch

CMS Open Payments · Tool

Integrity Implants Inc. dba Accelus vs Krystal Biotech Inc

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Krystal Biotech Inc has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 1,544, versus 412 for the other company. Its single largest recorded recipient represents 0.3% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Integrity Implants Inc. dba Accelus
HHI 412 · top recipient 0.1%
Ranked #1,366 of 1,838 companies by HHI
Krystal Biotech Inc
HHI 1,544 · top recipient 0.3%
Ranked #849 of 1,838 companies by HHI

Payment Overview

Total Payments
$1.6M
% of Industry
0.0%
Transactions
1,045
Avg per Transaction
$1.5K
Recipients
1,045
Avg per Recipient
$1.5K
Payment Types
4
Top Payment Type
Royalty or License
Total Payments
$1.6M
% of Industry
0.0%
Transactions
1,326
Avg per Transaction
$1.2K
Recipients
1,118
Avg per Recipient
$1.4K
Payment Types
5
Top Payment Type
Compensation for Services Other Than Consulting

Highlighted values indicate the higher figure for each metric.

Total payments compared

Integrity Implants Inc. dba Accelus vs Krystal Biotech Inc - total reported payments in CMS Open Payments PY2024

Integrity Implants Inc. dba…$1.6MKrystal Biotech Inc$1.6M

Payment Types Breakdown

Integrity Implants Inc. dba Accelus

Royalty or License $1.2M

78.6%

Consulting Fee $213.4K

13.4%

Travel and Lodging $84.2K

5.3%

Food and Beverage $42.1K

2.7%

Krystal Biotech Inc

Compensation for Services Other Than Consulting $91.3K

5.8%

Consulting Fee $68.9K

4.3%

Food and Beverage $33.9K

2.1%

Travel and Lodging $8.3K

0.5%

Education $369.12

0.0%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Integrity Implants Inc. dba Accelus

  1. 1

    Rohit Vasan

    $138,925.63 · 22 txns

  2. 2

    Paul Houle

    $134,792.60 · 86 txns

  3. 3

    Alan McGee

    $92,336.86 · 10 txns

  4. 4

    Domagoj Coric

    $91,643.31 · 8 txns

  5. 5

    Robert Norton

    $80,040.54 · 24 txns

Krystal Biotech Inc

  1. 1

    EVERETT SUTHERLAND

    $66,505.21 · 7 txns

  2. 2

    JOHN BROWNING

    $28,558.58 · 32 txns

  3. 3

    MERCEDES GONZALEZ

    $21,337.61 · 21 txns

  4. 4

    LARA WINE LEE

    $15,339.44 · 16 txns

  5. 5

    MATT MARINKOVICH

    $14,479.74 · 6 txns

Summary Comparison

Metric Integrity Implants Inc. dba Accelus Krystal Biotech Inc
Total Payments $1.6M $1.6M
% of Industry Total 0.0% 0.0%
Transaction Count 1,045 1,326
Avg per Transaction $1.5K $1.2K
Recipient Count 1,045 1,118
Avg per Recipient $1.5K $1.4K
Payment Type Count 4 5
Top Payment Type Royalty or License Compensation for Services Other Than Consulting

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.